Introduction
Materials and methods
Search strategy and study selection
Data extraction
Results
Search results
Idiopathic normal pressure hydrocephalus
Paper | Main intervention (if applicable) | Species | Age | Number of subjects | Method for quantifying glymphatic function | Main results | Comments/other results |
---|---|---|---|---|---|---|---|
Hasan-Olive et al. [8] | iNPH patients | Human | iNPH: 70.8 ± 8.8; reference subjects: 44.0 ± 16.5 | iNPH: n = 30; REF: n = 12 | AQP-4 immunogold labeling in astrocytic endfeet in brain biopsies. | Lower AQP-4 labeling in astrocytic endfeet directed toward capillary membranes in iNPH patients compared to reference subjects. | No objective measurement of glymphatic system function was done. |
Gastaldi et al. [9] | iNPH patients | Human | Median: 76 (65–86) | iNPH: n = 43; REF: n = 43; other neurodegenerative conditions: n = 35 | No method. | AQP-4 autoantibodies were not associated with iNPH, no iNPH patients has AQP-4 autoantibodies in serum och CSF. | |
Ringstad et al. [10] | iNPH patients | Human | iNPH: 71.3 ± 8.1; reference subjects: 41.1 ± 13.0 | iNPH: n = 15; REF: n = 8 | Intrathecal gadobutrol injection followed by repeated MRI imaging. | Slower enrichment of gadobutrol in several CSF spaces in iNPH patients in comparison with controls. | All results together indicate glymphatic dysfunction in iNPH patients. |
Eide and Ringstad [11] | iNPH patients | Human | iNPH: 70.4 ± 7.5; reference subjects: 38.6 ± 14.6 | iNPH: n = 30; REF: n = 8 | Intrathecal gadobutrol injection followed by repeated MRI imaging. | Gadobutrol was present in a higher degree in the entorhinal cortex, CSF, and subcortical white matter in the entorhinal cortex 24 h after injection in comparison with reference subjects. | The pathophysiological alterations suggest a dysfunction in the glymphatic system and may contribute to the development of dementia in iNPH. |
Jacobsen et al. [12] | iNPH patients | Human | iNPH: 71.0 ± 6.2; reference subjects: 49.6 ± 11.2 | iNPH: n = 31; REF: n = 13 | Intrathecal gadobutrol injection followed by repeated MRI imaging and image analysis of the visual pathway. | Delayed clearance of gadobutrol in several parts along the visual pathway in iNPH patients in comparison with controls. Delay of tracer penetration in the optic chiasm and optic tract in iNPH patients in comparison with controls. | An analysis of ICP also showed an association between pulsatile ICP-wave amplitude and a decrease in contrast agent penetration. |
Eide et al. [17] | iNPH patients | Human | 71.7 ± 5.8 | n = 95 | Intrathecal gadobutrol injection followed by repeated MRI imaging. | 0.25 mmol was the lowest sufficient dose to maintain diagnostic capacity in the two MRI biomarkers examined in the study. Enhancing the magnetic field strength of the MRI resulted in a greater signal boost compared to increasing the gadobutrol dosage. | The two MRI biomarkers used were: (1) Clearance of gadobutrol from the CSF 24 and 48 h after intrathecal injection. (2) Determination of the grade of ventricular CSF (contrast agent) reflux. |
Yokota et al. [13] | iNPH patients | Human | iNPH: 75.3 ± 7.3; pseudoNPH (piNPH): 75.7 ± 9.4; reference subjects: 75.7 ± 8.4 | iNPH: n = 12; piNPH: n = 12; REF: n = 12 | DTI-ALPS. | piNPH patients had significantly lower ALPS index than the control group. iNPH patients had significantly lower ALPS index than both the control group and the piNPH patients. | A decrease in ALPS index is highly indicative of glymphatic dysfunction. |
Kikuta et al. [14] | iNPH patients | Human | iNPH: 75.22 ± 5.12 | iNPH: n = 9 | DTI-ALPS. | iNPH patients that responded positively to shunt treatment (responders) had significantly lower ALPS index postoperatively than preoperatively, and this was not seen in non-responders. | These results may indicate a recovery of the glymphatic system after shunt surgery in responders. |
Eide [15] | iNPH patients | Human | iNPH: 66.2 ± 5.3, controls 55.6 ± 12.0 | iNPH: n = 27, controls n = 8 | Superficial cortical layers were examined using light microscope. Additionally, overnight ICP monitoring was performed. | iNPH patients brain cortex examination showed reduced expression of AQP4 expression at astrocytic endfeet and showed abnormally high pulsatile ICP when measured overnight. | iNPH is characterized by cellular changes in the glio-neurovascular interface. This is suggested by authors to possibly reflect pathophysiology of the condition. |
Georgiopoulos et al. [16] | iNPH patients | Human | iNPH: 77 years, controls 73 years | iNPH: n = 30, healthy controls n = 27 | DTI-ALPS. | Lower ALPS index score was found in iNPH patients compared with healthy controls. Healthy female controls had a higher ALPS index score than males. | ALPS index could serve as a marker of severity of iNPH but could be influenced by biological gender and needs further validation. |
Idiopathic intracranial hypertension
Paper | Main intervention | Species | Age | Number of subjects | Method for quantifying glymphatic function | Main results | Comments/other results |
---|---|---|---|---|---|---|---|
Eide et al. [18] | IIH patients | Human | IIH: 35.6 ± 12.2; REF: 32.1 ± 6.5 | IIH: n = 15; REF: n = 15 | Intrathecal injection of gadobutrol and MRI. | Higher enrichment and late clearance of gadobutrol in IIH patients than reference subjects. | IIH patients with pathological pulsatility of ICP were observed to have even higher enrichment and later clearance of gadobutrol in the brain parenchyma than IIH patients without pathological ICP pulsatility. |
Jones et al. [19] | IIH patients | Human | IIH: 34.8 ± 9.2; REF: 37.8 ± 13.5 | IIH: n = 32; REF: n = 21 | Quantification of PVS visibility on MRI (PVS burden). | Higher PVS burden in patients with IIH than reference subjects in centrum semiovale and basal ganglia. | The results may indicate a role of glymphatic dysfunction in IIH, although no objective quantification of glymphatic function was carried out. |
Liu et al. [20] | IIH patient | Human | 39 years | n = 1 | Normalizing of ICP and improvement clinical symptoms. | Patient with IIH, bilateral sinus transversus stenosis, and CSVD. After antihypertensive, antiplatelet, antisclerotic, and homocysteine-lowering therapies, the symptoms regressed and ICP normalized. | Authors suggest CSVD in patients with IIH and venous sinus stenosis disturbs the compensatory effect of glymphatic system in patients with IIH. |
Subarachnoid hemorrhage
Stroke
Intracranial tumors
Paper (author and year) | Type of tumor | Species | Age | Number of subjects | Method for quantifying glymphatic function | Main results | Comments/other results |
---|---|---|---|---|---|---|---|
Toh and Siow [47] | Glioma | Human | 47.4 ± 15.5 | n = 201 | Calculation of ALPS index using DTI-ALPS. | Grade 4 gliomas were associated with a lower ALPS index than grade II and grade III gliomas. No significant difference in the ALPS index value was observed between grade II and grade III gliomas. | The presence of an IDH mutation was associated with higher ALPS index values. Volume of peritumoral edema was negatively correlated with the ALPS index value. |
Ma et al. [48] | Induced glioma via injection of GL261 cells into the right striatum | Mouse | 2–3 months | N/A | Intracisternal tracer injection followed by analysis of signal intensity in the saphenous vein, dcLNs and mandibular lymph nodes, and fluorescence imaging of cranial nerves after 60 min. Intracisternal Gadospin D injection followed by MRI imaging. | Significantly reduced signal intensity in saphenous vein, dcLNs, and mandibular lymph nodes in mice with glioma in comparison with control mice. Decreased CSF flow along several cranial nerves in mice with glioma. Complete blockage of clearance of intracisternal Gadospin D in mice with gliomas. | An increase in spinal outflow of CSF was shown in mice with gliomas, indicating a redirection of CSF outflow pathways caused by the gliomas. All results together indicate glymphatic and cerebral lymphatic dysfunction following glioma induction. |
Xu et al. [49] | Induced glioma via injection of rat glioma C6 cells into the right striatum | Rat | 6 weeks | N/A | Intracisternal gadobutrol injection followed by repeated MRI imaging. Intracisternal Evans blue injection followed by macroscopic analysis. | Increased MRI signal in the olfactory bulbs 3–4 h after gadobutrol injection. Retrograde tracer flow into the ventricles in rats. Lower tracer and gadobutrol influx into the glioma than in healthy tissue, and mostly limited to the periphery of the tumor. Evans blue and gadobutrol signal strength was also higher in the side contralateral to the tumor in comparison to the tumor side. | AQP-4 expression in and around the glioma was also decreased. Results indicate that glymphatic flow is obstructed and redirected in rats with gliomas, and healthy tissue seems to compensate for the glioma-containing side in terms of glymphatic outflow pathways. |
Toh et al. [50] | Brain metastases | Human | 56.9 ± 11.6 | n = 56 | Calculation of ALPS index using DTI-ALPS. | Peritumoral brain edema (PTBE) was negatively correlated with ALPS index. | Negative correlation with ALPS index values could be indicative of a connection between PTBE and glymphatic dysfunction. |
Toh et al. [51] | Meningioma | Human | 58.8 ± 13.5 | n = 80 | Calculation of ALPS index using DTI-ALPS. | Meningiomas without PTBE were associated with a higher ALPS than normal patients and meningiomas with PTBE. | Decrease in glymphatic function may be linked to the formation of PTBE. |
Li et al. [52] | Rats with spontaneous pituitary tumor | Rat | 22–24 months | n = 14 | Intracisternal contrast injection, evaluated with MRI T2-weighted and dynamic 3D T1-weighted. | A lower incidence of enhancement of glymphatic influx nodes and pituitary and pineal recesses in rats with pituitary tumors. | The glymphatic system seems to be affected in rats with spontaneous pituitary tumor. |